Paul Stoffels, MD, was vice chairman of the executive committee and CSO of Johnson & Johnson, setting the company-wide innovation agenda and leading the pharmaceutical research and product pipeline as well as the external initiatives. Prior to that, he was worldwide chairman pharmaceuticals of Johnson & Johnson, which significantly rejuvenated its product pipeline and adopted a transformational R&D operating model, resulting in the launch of 25 innovative medicines across the globe. Paul joined Johnson & Johnson in 2002, with the acquisition of Virco and Tibotec, where he was CEO and chairman, respectively, and led the development of several breakthrough products for the treatment of HIV. Paul was a member of the board of directors of Galapagos NV from its incorporation until 2002.